HUMAN EPIDERMAL GROWTH FACTOR 2 NEGATIVE CARCINOMA OF BREAST
Clinical trials for HUMAN EPIDERMAL GROWTH FACTOR 2 NEGATIVE CARCINOMA OF BREAST explained in plain language.
Never miss a new study
Get alerted when new HUMAN EPIDERMAL GROWTH FACTOR 2 NEGATIVE CARCINOMA OF BREAST trials appear
Sign up with your email to follow new studies for HUMAN EPIDERMAL GROWTH FACTOR 2 NEGATIVE CARCINOMA OF BREAST, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
First patients to try groundbreaking oral cancer pill
Disease control Recruiting nowThis is the first study in people to test a new oral drug called NKT3964. It aims to see if the drug is safe and can help control advanced cancers that have spread and stopped responding to standard treatments. The study will enroll adults with specific advanced solid tumors, inc…
Matched conditions: HUMAN EPIDERMAL GROWTH FACTOR 2 NEGATIVE CARCINOMA OF BREAST
Phase: PHASE1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New hope for Tough-to-Treat breast cancer: two drugs vs. one
Disease control Recruiting nowThis study is testing if combining two drugs, capecitabine and elacestrant, works better than just capecitabine alone for people with advanced, hormone-sensitive breast cancer. It's for patients whose cancer has stopped responding to a common class of prior medications. The main …
Matched conditions: HUMAN EPIDERMAL GROWTH FACTOR 2 NEGATIVE CARCINOMA OF BREAST
Phase: PHASE2 • Sponsor: Kristina A. Fanucci • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
New pill targets Tough-to-Treat cancers in early trial
Disease control Recruiting nowThis early-stage study is testing a new oral medication called INX-315 in people with advanced cancers that have spread or stopped responding to standard treatments. It aims to find a safe dose and see if the drug can help control cancers like certain types of breast and ovarian …
Matched conditions: HUMAN EPIDERMAL GROWTH FACTOR 2 NEGATIVE CARCINOMA OF BREAST
Phase: PHASE1, PHASE2 • Sponsor: Incyclix Bio • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC
-
New hope for nigerian women with aggressive breast cancer
Disease control Recruiting nowThis study is testing a targeted cancer treatment approach for Nigerian women with HER2-positive breast cancer. Participants receive a combination of targeted drugs and chemotherapy both before and after surgery. The research aims to see how effective and safe this treatment is f…
Matched conditions: HUMAN EPIDERMAL GROWTH FACTOR 2 NEGATIVE CARCINOMA OF BREAST
Phase: PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Mar 12, 2026 13:50 UTC